KR970704429A - 심혈관 질환의 치료를 위한 드롤록시펜의 용도(use of droloxifene for the treatment of cardiovascular diseases) - Google Patents

심혈관 질환의 치료를 위한 드롤록시펜의 용도(use of droloxifene for the treatment of cardiovascular diseases) Download PDF

Info

Publication number
KR970704429A
KR970704429A KR1019970700330A KR19970700330A KR970704429A KR 970704429 A KR970704429 A KR 970704429A KR 1019970700330 A KR1019970700330 A KR 1019970700330A KR 19970700330 A KR19970700330 A KR 19970700330A KR 970704429 A KR970704429 A KR 970704429A
Authority
KR
South Korea
Prior art keywords
treatment
cardiovascular diseases
droloxifene
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
KR1019970700330A
Other languages
English (en)
Other versions
KR100212352B1 (ko
Inventor
롤란트 뢰저
미카엘 슐리악
데이비드 디 톰슨
Original Assignee
스피겔 알렌 제이
화이자 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스피겔 알렌 제이, 화이자 인코포레이티드 filed Critical 스피겔 알렌 제이
Publication of KR970704429A publication Critical patent/KR970704429A/ko
Application granted granted Critical
Publication of KR100212352B1 publication Critical patent/KR100212352B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

심현관 질환의 치료에 대한 드롤록시펜의 용도를 개시한다.

Description

심혈관 질환의 치료를 위한 드롤록시펜의 용도(USE OF DROLOXIFENE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (5)

  1. 양성 전립선 비대증을 앓고 있는 포유동물에게 치료에 유효한 양의 드롤록시펜 또는 그 약학적으로 허용가능한 염을 투여함을 포함함을 특징으로 하는, 양성 전립선 비대증의 치료 방법.
  2. 심혈관 질환의 치료가 필요한 포유동물에게 상기 심혈관 질환의 치료 또는 예방에 유효한 양의 드롤록시펜 또는 그의 약학적으로 허용가능한 염을 투여함을 포함함을 특징으로 하는, 심혈관 질환의 치료 또는 예방 방법.
  3. 제2항에 있어서, 상기 심혈관 질환이 죽상동맥경화중인 방법.
  4. 제2항에 있어서, 상기 심혈관 질환이 고콜레스테롤혈증인 방법.
  5. 제2항에 있어서, 상기 약학적으로 허용가능한 염이 시트로산 염인 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019970700330A 1994-07-19 1995-05-26 드롤록시펜을 포함하는 심혈관 질환의 치료를 위한 약학 조성물 KR100212352B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/276,969 US5441986A (en) 1994-07-19 1994-07-19 Estrogen agonists as remedies for prostate and cardiovascular diseases
US08/276,969 1994-07-19
US8/276,969 1994-07-19
PCT/IB1995/000403 WO1996002242A1 (en) 1994-07-19 1995-05-26 Use of droloxifene for the treatment of cardiovascular diseases

Publications (2)

Publication Number Publication Date
KR970704429A true KR970704429A (ko) 1997-09-06
KR100212352B1 KR100212352B1 (ko) 1999-08-02

Family

ID=23058874

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1019970700330A KR100212352B1 (ko) 1994-07-19 1995-05-26 드롤록시펜을 포함하는 심혈관 질환의 치료를 위한 약학 조성물
KR1019970700331A KR100221854B1 (ko) 1994-07-19 1995-05-26 드롤록시펜을 포함하는 전립선 질환을 치료하기 위한 약학 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1019970700331A KR100221854B1 (ko) 1994-07-19 1995-05-26 드롤록시펜을 포함하는 전립선 질환을 치료하기 위한 약학 조성물

Country Status (17)

Country Link
US (4) US5441986A (ko)
EP (3) EP0771194A1 (ko)
JP (2) JP2930424B2 (ko)
KR (2) KR100212352B1 (ko)
CN (2) CN1152868A (ko)
AU (2) AU694220B2 (ko)
CA (2) CA2195213C (ko)
FI (2) FI970215A (ko)
HK (1) HK1000697A1 (ko)
HU (2) HUT77391A (ko)
IL (2) IL114585A (ko)
MX (2) MX9700534A (ko)
MY (1) MY113079A (ko)
NZ (2) NZ285158A (ko)
TW (1) TW403649B (ko)
WO (2) WO1996002243A1 (ko)
ZA (2) ZA955963B (ko)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US5770609A (en) 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6395494B1 (en) * 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en) 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
US5441986A (en) * 1994-07-19 1995-08-15 Pfizer Inc. Estrogen agonists as remedies for prostate and cardiovascular diseases
ATE377418T1 (de) 1995-06-07 2007-11-15 Poniard Pharmaceuticals Inc Vorbeugung und behandlung von kardiovaskulären beschwerden mit tamoxifen-analogen
US5985932A (en) * 1996-02-28 1999-11-16 Pfizer Inc Inhibition of autoimmune diseases
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
US5719190A (en) * 1996-02-28 1998-02-17 Pfizer Inc. Inhibition of myeloperoxidase activity
US5726207A (en) * 1996-02-28 1998-03-10 Pfizer Inc. Protection of ischemic myocardium against reperfusion damage
IL120270A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to treat osteoporosis
US5733937A (en) * 1996-02-28 1998-03-31 Pfizer Inc. Methods for alleviating symptoms of premenstrual syndrome and late luteal phase dysphoric disorder
IL120262A (en) * 1996-02-28 2001-01-28 Pfizer Droloxifene and derivatives thereof for use in increasing serum testosterone levels
IL120269A0 (en) * 1996-02-28 1997-06-10 Pfizer 1,1,2-triphenylbut-1-ene derivatives for treating Alzheimer's disease
IL120263A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to prevent bone loss-progesterone and estrogen agonists
IL120268A0 (en) * 1996-02-28 1997-06-10 Pfizer Use of (E)-1-[4'-(2-alkylaminoethioxy)phenyl]1-(3'-hydroxyphenyl)-2-phenylbut-1-enes in inhibiting pathological conditions
US6034102A (en) * 1996-11-15 2000-03-07 Pfizer Inc Atherosclerosis treatment
US6114395A (en) * 1996-11-15 2000-09-05 Pfizer Inc. Method of treating atherosclerosis
US6069175A (en) * 1996-11-15 2000-05-30 Pfizer Inc. Estrogen agonist/antagonists treatment of atherosclerosis
AU6959898A (en) * 1997-04-11 1998-11-11 David J. Grainger Compounds and therapies for the prevention of vascular and non-vascular pathol ogies
US20040186185A1 (en) * 1998-05-07 2004-09-23 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
US6413533B1 (en) * 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US20040092602A1 (en) * 1998-05-07 2004-05-13 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
FI982733A (fi) 1998-12-17 2000-06-18 Orion Yhtymae Oyj Trifenyylietyleeniantiestrogeenien liukoisia koostumuksia
DK1175433T3 (da) 1999-05-04 2005-09-19 Strakan Int Ltd Androgenglycosider og androgen aktivitet deraf
AU5957500A (en) 1999-07-06 2001-01-22 Endorecherche Inc. Methods of treating and/or suppressing weight gain
TW593256B (en) 1999-11-16 2004-06-21 Hormos Medical Oy Ltd Triphenylalkene derivatives and their use as selective estrogen receptor modulators
CO5271709A1 (es) * 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos
US20080249183A1 (en) * 2001-11-29 2008-10-09 Steiner Mitchell S Treatment of androgen-deprivation induced osteoporosis
US20040248989A1 (en) 2003-06-05 2004-12-09 Risto Santti Method for the treatment or prevention of lower urinary tract symptoms
US20060270641A1 (en) * 2005-05-31 2006-11-30 Steiner Mitchell S Method for chemoprevention of prostate cancer
RU2480207C2 (ru) * 2006-05-22 2013-04-27 Хормос Медикал Лтд. Способ лечения хронического абактериального простатита селективными модуляторами рецепторов эстрогена или ингибиторами ароматазы
US7504530B2 (en) * 2007-02-14 2009-03-17 Hormos Medical Ltd. Methods for the preparation of fispemifene from ospemifene
JP5363344B2 (ja) * 2007-02-14 2013-12-11 ホルモス メディカル リミテッド 治療に有用なトリフェニルブテン誘導体の調製方法
WO2014060639A1 (en) 2012-10-19 2014-04-24 Fermion Oy A process for the preparation of ospemifene

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3046719C2 (de) * 1980-12-11 1983-02-17 Klinge Pharma GmbH, 8000 München 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel
DE3323321A1 (de) * 1983-06-24 1985-01-03 Schering AG, 1000 Berlin und 4709 Bergkamen Prophylaxe und therapie von koronaren herzkrankheiten durch senkung des oestrogenspiegels
US5262319A (en) * 1985-04-19 1993-11-16 Oncogene Science, Inc. Method for obtaining bone marrow free of tumor cells using transforming growth factor β3
FR2619383B1 (fr) * 1987-08-12 1989-12-08 Inst Vaisseaux Sang Proteine a activite vasculaire, derivee des monocytes et ses analogues, procede pour son extraction et leurs utilisations en therapeutique et pour la preparation d'anticorps
JPH04312526A (ja) * 1991-04-09 1992-11-04 Fujisawa Pharmaceut Co Ltd 骨疾患治療剤
DE4401554A1 (de) * 1993-02-16 1994-08-18 Freund Andreas Präparat zur Therapie und Prophylaxe von Erkrankungen, die bei Imbalancen von Plasmalipiden auftreten
US5384332A (en) * 1994-05-11 1995-01-24 Eli Lilly And Company Methods for inhibiting aortal smooth muscle cell proliferation and restenosis with 1,1,2-triphenylbut-1-ene derivatives
US5426123A (en) * 1994-05-11 1995-06-20 Eli Lilly And Company Method for lowering serum cholesterol with 1,1,2-triphenylbut-1-ene derivatives
US5455275A (en) * 1994-05-11 1995-10-03 Eli Lilly And Company Methods for inhibiting endometriosis and uterine fibroid disease with 1,1,2-triphenylbut-1-ene derivatives
US5441986A (en) * 1994-07-19 1995-08-15 Pfizer Inc. Estrogen agonists as remedies for prostate and cardiovascular diseases

Also Published As

Publication number Publication date
NZ285159A (en) 2000-10-27
AU2416995A (en) 1996-02-16
MY113079A (en) 2001-11-30
WO1996002242A1 (en) 1996-02-01
CN1076967C (zh) 2002-01-02
MX9700534A (es) 1997-04-30
EP1029540A3 (en) 2001-05-16
FI970215A0 (fi) 1997-01-17
FI970214A0 (fi) 1997-01-17
HU9700163D0 (en) 1997-03-28
KR100212352B1 (ko) 1999-08-02
IL114586A (en) 2000-06-29
JPH09507859A (ja) 1997-08-12
AU689257B2 (en) 1998-03-26
JPH09507860A (ja) 1997-08-12
FI970214A (fi) 1997-01-17
ZA955964B (en) 1997-01-20
FI970215A (fi) 1997-01-17
JP2930424B2 (ja) 1999-08-03
CN1153473A (zh) 1997-07-02
US5441986A (en) 1995-08-15
KR970704430A (ko) 1997-09-06
CA2195093A1 (en) 1996-02-01
CN1152868A (zh) 1997-06-25
KR100221854B1 (ko) 1999-09-15
CA2195213A1 (en) 1996-02-01
WO1996002243A1 (en) 1996-02-01
ZA955963B (en) 1997-01-20
AU2417095A (en) 1996-02-16
EP0769941A1 (en) 1997-05-02
HK1000697A1 (en) 2002-05-10
IL114586A0 (en) 1995-11-27
EP0771194A1 (en) 1997-05-07
MX9700538A (es) 1997-04-30
CA2195093C (en) 2000-03-07
AU694220B2 (en) 1998-07-16
HUT77391A (hu) 1998-04-28
CA2195213C (en) 2000-03-14
US5852059A (en) 1998-12-22
NZ285158A (en) 2000-07-28
HUT77392A (hu) 1998-04-28
EP1029540A2 (en) 2000-08-23
US5827892A (en) 1998-10-27
TW403649B (en) 2000-09-01
HU9700162D0 (en) 1997-03-28
IL114585A0 (en) 1995-11-27
IL114585A (en) 2000-01-31
US5902830A (en) 1999-05-11

Similar Documents

Publication Publication Date Title
KR970704429A (ko) 심혈관 질환의 치료를 위한 드롤록시펜의 용도(use of droloxifene for the treatment of cardiovascular diseases)
CA2289717A1 (en) Novel therapy for constipation
RU94041223A (ru) Средство для лечения мотонейроновых заболеваний
IS1907B (is) Notkun klóbindiefnisins klíókínól við að framleiða lyfjablöndu til að meðhöndla Alzheimers-sjúkdóm
HUT60630A (en) Process or producing peroral pharmaceutical compositions suitable for treating internal diseases of inflammatory nature
EP1014996A4 (en) SACCHARIDE COMPOSITIONS AND METHODS FOR SPECIFIC TREATMENT OF ALZHEIMER'S DISEASE AND OTHER AMYLOIDOSIS
KR950002785A (ko) 골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜
DK1392329T3 (da) Anvendelse af sulodexid til behandling af inflammatorisk tarmsygdom
BE900564A (fr) Composition pharmaceutique pour le traitement d'arteriopathies peripheriques.
MY118986A (en) Use of (alpha)-1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
KR950016760A (ko) 치질 치료제
DK0671414T3 (da) Dermatansulfatsammensætning som antitrombotisk middel
EA200000242A1 (ru) Применение фанхинона для лечения болезни альцгеймера
WO2001003688A3 (en) Treatment of cyclooxygenase-2 mediated disorders using conjugated fatty acid compounds
DE69103773D1 (de) Derivate von hydroxaminsäure die lipoxygenase hemmen.
DE69729201T2 (de) Sulfonfluoride zur behandlung von der alzheimerischen krankheit
KR970704442A (ko) 일시적인 병소 허혈에 의해 유발된 재관류 손상을 치료하기 위한 (S)-아데노실-L-메티오닌(SAMe) 및 그의 생리학상 적합한 염의 용도(Use of (S)-Adenosy-L-Methionine(SAMe) and lts Physiologically Compatible Salts for Treating Reperfusion Damage Triggered by Temporary Focal lschaemia)
NO944524L (no) Anvendelse av (E)-2-(p-fluorfenetyl)-3-fluorallylamin ved behandling av Alzheimers sykdom
KR970058710A (ko) 담석의 접촉성 용해제
UA39988C2 (uk) Антимікробний засіб" асперсепт" та спосіб лікування та профілактики інфекційних уражень шкіри за допомогою цього засобу
CA2099667A1 (en) Agent for treating hepatic diseases
MX9605153A (es) Agentes farmaceuticos para el tratamiento de enfermedades inflamatorias cronicas y agudas.
UA30393A (uk) Спосіб лікування коронарного атеросклерозу
CA2288966A1 (en) Preventives and remedies for ulcerous colitis and/or crohn's disease
MY110416A (en) Composition for the treatment of schizophrenia.

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20020502

Year of fee payment: 4

LAPS Lapse due to unpaid annual fee